Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals.

Abstract

OBJECTIVE:

NSAID-exacerbated respiratory disease (NERD) is characterized by exacerbation of respiratory symptoms after NSAID intake. While research for specific treatment options continues in patients who cannot tolerate or are unresponsive to aspirin treatment after aspirin desensitization (ATAD), biologicals have emerged as a new therapeutic option in NERD patients. The aim of this study was to compare the quality of life, and the sinonasal and respiratory outcomes of NERD patients treated with ATAD or biologicals.

METHODS:

Patients who have been followed up at a tertiary care allergy center and who have been receiving at least one of ATAD, mepolizumab or omalizumab for at least six months were included. Evaluations were made using sinonasal outcome test (SNOT-22), asthma control test (ACT), short form-36 (SF-36), blood eosinophil counts, need for recurrent functional endoscopic sinus surgeries (FESS), and asthma or rhinitis exacerbations requiring oral corticosteroids (OCS).

RESULTS:

A total of 59 patients comprised of 35 (59%) females and 24 (41%) males with a mean age of 46.1 (min-max, 20-70) years were included. The baseline blood eosinophil count was higher, and a significant decrease in blood eosinophil counts was observed in the mepolizumab group compared to ATAD group (p = 0.001, p < 0.001, respectively). At follow-up, the rate of recurrent FESS was lower in the group that received mepolizumab (p = 0.02).

CONCLUSIONS:

In NERD patients, mepolizumab significantly decreased blood eosinophil counts and recurrent FESS. There was no significant difference between the patients receiving ATAD or mepolizumab regarding other clinical parameters.

• Authors: Gülseren Tuncay, Ebru Damadoglu, Melek Cihanbeylerden, Ozge Can Bostan, Hazal Kayıkcı, Serdar Özer, Gül Karakaya, Ali Fuat Kalyoncu
• Journal: The Journal of asthma : official journal of the Association for the Care of Asthma (J Asthma) Vol. 60 Issue 10 Pg. 1885-1894 (10 2023) ISSN: 1532-4303 [Electronic] England
• PMID: 36971076 (Publication Type: Journal Article)

Chemical References

• Aspirin
• Anti-Inflammatory Agents, Non-Steroidal
• Biological Products

Topics

• Male
• Female
• Humans
• Middle Aged
• Aspirin (adverse effects)
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
• Asthma (diagnosis)
• Biological Products (adverse effects)
• Quality of Life